Valuation : Immunovia AB

Market Cap 95.92M 10.08M 8.65M 8.1M 7.42M 13.97M 963M 14.01M 37.5M 485M 37.84M 37.03M 1.61B P/E 2026 *
-1.43x
P/E 2027 * -3.57x
Enterprise Value 60.92M 6.4M 5.5M 5.14M 4.71M 8.87M 611M 8.9M 23.82M 308M 24.04M 23.52M 1.02B EV / Sales 2026 *
19x
EV / Sales 2027 * 3.81x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-9.40%
Current month-20.60%
1 month-19.44%
3 months-36.34%
6 months-42.27%
Current year-37.18%
1 week 0.14
Extreme 0.139
0.16
1 month 0.14
Extreme 0.139
0.19
Current year 0.14
Extreme 0.139
0.25
1 year 0.14
Extreme 0.139
0.96
3 years 0.14
Extreme 0.139
4.73
5 years 0.14
Extreme 0.139
141.5
10 years 0.14
Extreme 0.139
298.5
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 69 26/05/2023
Director/Board Member 51 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
15/11/22 Buy

Chief Executive Officer

150,000 0.6628%
24/05/22 Buy

Chief Executive Officer

100,000 0.4419%
21/05/22 Buy

Chief Executive Officer

100,000 0.4419%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-9.40%-85.15%-85.36% 10.08M
+0.18%+1.99%+28.09%-28.64% 17.96B
+15.78%+0.07%-30.47%+110.64% 1.66B
+2.75%+3.16%-44.83%-80.13% 1.05B
+1.71%-2.27%-23.68%+23.59% 959M
+0.05%0.00%+61.48%-5.62% 779M
+2.67%+1.05%-38.28%-44.75% 693M
+3.43%-8.53%-44.27%-48.79% 565M
+0.67%+1.63%-37.80%-35.79% 461M
+7.04%+7.25%+76.19%+53.95% 459M
Average +3.46%+0.89%-13.87%-14.09% 2.46B
Weighted average by Cap. +1.68%+1.15%+16.14%-18.20%

Financials

2026 *2027 *
Net sales 3.2M 336K 289K 270K 247K 466K 32.12M 467K 1.25M 16.19M 1.26M 1.24M 53.57M 17.3M 1.82M 1.56M 1.46M 1.34M 2.52M 174M 2.53M 6.76M 87.51M 6.83M 6.68M 290M
Net income -87M -9.14M -7.85M -7.35M -6.73M -12.67M -873M -12.71M -34.01M -440M -34.32M -33.58M -1.46B -76M -7.99M -6.86M -6.42M -5.88M -11.07M -763M -11.1M -29.71M -384M -29.98M -29.34M -1.27B
Net Debt -35M -3.68M -3.16M -2.96M -2.71M -5.1M -351M -5.11M -13.68M -177M -13.81M -13.51M -586M -30M -3.15M -2.71M -2.53M -2.32M -4.37M -301M -4.38M -11.73M -152M -11.84M -11.58M -502M
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume
28/08/26 SEK 0.1426 0.00% 1,594,496
27/08/26 SEK 0.1426 0.00% 2,237,596
26/08/26 SEK 0.1426 -5.31% 7,229,753
25/08/26 SEK 0.1506 -1.44% 3,728,896
24/08/26 SEK 0.1528 +0.39% 4,958,717

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMNOV Stock